Literature DB >> 11928713

Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors.

Ryo Niimi1, Akio Nakamura, Yukishige Yanagawa.   

Abstract

The present study was designed to clarify the role of angiotensin II (Ang II) in modulating renal tumor necrosis factor (TNF)-alpha and interleukin-6 (IL-6) production and to investigate the effect of one dose of Ang II inhibitor on cytokines production following lipopolysaccharide (LPS) to cause endotoxemia. Two studies were performed: 1) Ang II was infused intravenously at a rate of 0.2 microg/kg per minute for 4 h in rats and then kidneys were collected to assay TNF-alpha and IL-6 mRNA levels; 2) Four-week-old Wistar rats pre-treated with angiotensin-converting enzyme inhibitor, enalapril, or type I Ang II-receptor antagonist, TCV-116, were injected with LPS (0.1, 0.5, 1.0 mg, i.p.), and then 2 or 4 h later, kidneys were collected to assay TNF-alpha, IL-6, renin and angiotensinogen mRNA levels. After a 4-h intravenous infusion of Ang II, renal TNF-alpha or IL-6 mRNA level significantly increased 1.9-fold or 2.1-fold (each P<0.05) to the control level, respectively. LPS stimulated TNF-alpha, IL-6 and angiotensinogen mRNA levels in the kidney but in rats given enalapril or TCV-116, LPS-induced IL-6 and TNF-alpha mRNA levels were completely suppressed (each P<0.05). This suggests that a single dose of renin-angiotensin system inhibitor suppressed renal IL-6 and TNF-alpha production and may prevent cytokine-induced renal damage during endotoxemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11928713     DOI: 10.1254/jjp.88.139

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  6 in total

1.  Immunosuppressive treatment protects against angiotensin II-induced renal damage.

Authors:  Dominik N Muller; Erdenechimeg Shagdarsuren; Joon-Keun Park; Ralf Dechend; Eero Mervaala; Franziska Hampich; Anette Fiebeler; Xinsheng Ju; Piet Finckenberg; Jürgen Theuer; Christiane Viedt; Joerg Kreuzer; Harald Heidecke; Hermann Haller; Martin Zenke; Friedrich C Luft
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

Authors:  Miklos Z Molnar; Kamyar Kalantar-Zadeh; Evan H Lott; Jun Ling Lu; Sandra M Malakauskas; Jennie Z Ma; Darryl L Quarles; Csaba P Kovesdy
Journal:  J Am Coll Cardiol       Date:  2013-11-21       Impact factor: 24.094

3.  The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.

Authors:  Shigeru Tanaka; Toshiharu Ninomiya; Ritsuko Katafuchi; Kosuke Masutani; Masaharu Nagata; Akihiro Tsuchimoto; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Clin Exp Nephrol       Date:  2015-11-12       Impact factor: 2.801

4.  The Influence of ACE Insertion/Deletion Gene Polymorphism on the Risk of IgA Nephropathy: A Debatable Topic.

Authors:  Fen-Fen Chu; Shi-Kun Yang; Wen-Li Zeng
Journal:  Genet Res (Camb)       Date:  2021-11-18       Impact factor: 1.588

5.  Chymase activities and survival in endotoxin-induced human chymase transgenic mice.

Authors:  Kazi Rafiq; Yu-Yan Fan; Shamshad J Sherajee; Yoshimasa Takahashi; Junji Matsuura; Naoki Hase; Hirohito Mori; Daisuke Nakano; Hideki Kobara; Hirofumi Hitomi; Tsutomu Masaki; Hidenori Urata; Akira Nishiyama
Journal:  Int J Med Sci       Date:  2014-01-11       Impact factor: 3.738

6.  The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats.

Authors:  P L M Dalpiaz; A Z Lamas; I F Caliman; A R S Medeiros; G R Abreu; M R Moysés; T U Andrade; M F Alves; A K Carmona; N S Bissoli
Journal:  Braz J Med Biol Res       Date:  2013-02-01       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.